A citation-based method for searching scientific literature

Michelle L Boland, Rhianna C Laker, Karly Mather, Arkadiusz Nawrocki, Stephanie Oldham, Brandon B Boland, Hilary Lewis, James Conway, Jacqueline Naylor, Silvia Guionaud, Michael Feigh, Sanne S Veidal, Louise Lantier, Owen P McGuinness, Joseph Grimsby, Cristina M Rondinone, Lutz Jermutus, Martin R Larsen, James L Trevaskis, Christopher J Rhodes. Nat Metab 2020
Times Cited: 66







List of co-cited articles
1084 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
944
36

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Philip Ambery, Victoria E Parker, Michael Stumvoll, Maximilian G Posch, Tim Heise, Leona Plum-Moerschel, Lan-Feng Tsai, Darren Robertson, Meena Jain, Marcella Petrone,[...]. Lancet 2018
152
33

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Philip N Newsome, Kristine Buchholtz, Kenneth Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu, Arun J Sanyal, Anne-Sophie Sejling, Stephen A Harrison. N Engl J Med 2021
357
31

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
Mark L Hartman, Arun J Sanyal, Rohit Loomba, Jonathan M Wilson, Amir Nikooienejad, Ross Bray, Chrisanthi A Karanikas, Kevin L Duffin, Deborah A Robins, Axel Haupt. Diabetes Care 2020
91
24

Glucagon-like peptide 1 (GLP-1).
T D Müller, B Finan, S R Bloom, D D'Alessio, D J Drucker, P R Flatt, A Fritsche, F Gribble, H J Grill, J F Habener,[...]. Mol Metab 2019
439
24

Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
S J Henderson, A Konkar, D C Hornigold, J L Trevaskis, R Jackson, M Fritsch Fredin, R Jansson-Löfmark, J Naylor, A Rossi, M A Bednarek,[...]. Diabetes Obes Metab 2016
137
22

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
344
22

Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.
Rajaa Nahra, Tao Wang, Kishore M Gadde, Jan Oscarsson, Michael Stumvoll, Lutz Jermutus, Boaz Hirshberg, Philip Ambery. Diabetes Care 2021
42
35

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
359
21

GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice.
Naim Panjwani, Erin E Mulvihill, Christine Longuet, Bernardo Yusta, Jonathan E Campbell, Theodore J Brown, Catherine Streutker, Dianne Holland, Xiemin Cao, Laurie L Baggio,[...]. Endocrinology 2013
246
21

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Vlad Ratziu, Stephen A Harrison, Sven Francque, Pierre Bedossa, Philippe Lehert, Lawrence Serfaty, Manuel Romero-Gomez, Jérôme Boursier, Manal Abdelmalek, Steve Caldwell,[...]. Gastroenterology 2016
636
19


Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Zobair M Younossi, Vlad Ratziu, Rohit Loomba, Mary Rinella, Quentin M Anstee, Zachary Goodman, Pierre Bedossa, Andreas Geier, Susanne Beckebaum, Philip N Newsome,[...]. Lancet 2019
488
18

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways.
Günaj Rakipovski, Bidda Rolin, Jane Nøhr, Ib Klewe, Klaus S Frederiksen, Robert Augustin, Jacob Hecksher-Sørensen, Camilla Ingvorsen, Joseph Polex-Wolf, Lotte Bjerre Knudsen. JACC Basic Transl Sci 2018
136
18

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
207
16

Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist.
Victoria E R Parker, Darren Robertson, Tao Wang, David C Hornigold, Marcella Petrone, Aidan T Cooper, Maximilian G Posch, Tim Heise, Leona Plum-Moerschel, Heike Schlichthaar,[...]. J Clin Endocrinol Metab 2020
35
31

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Arun Sanyal, Edgar D Charles, Brent A Neuschwander-Tetri, Rohit Loomba, Stephen A Harrison, Manal F Abdelmalek, Eric J Lawitz, Dina Halegoua-DeMarzio, Sudeep Kundu, Stephanie Noviello,[...]. Lancet 2019
241
16

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Brent A Neuschwander-Tetri, Rohit Loomba, Arun J Sanyal, Joel E Lavine, Mark L Van Natta, Manal F Abdelmalek, Naga Chalasani, Srinivasan Dasarathy, Anna Mae Diehl, Bilal Hameed,[...]. Lancet 2015
16

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.
Jonathan W Day, Nickki Ottaway, James T Patterson, Vasily Gelfanov, David Smiley, Jas Gidda, Hannes Findeisen, Dennis Bruemmer, Daniel J Drucker, Nilika Chaudhary,[...]. Nat Chem Biol 2009
390
15

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Zobair M Younossi, Aaron B Koenig, Dinan Abdelatif, Yousef Fazel, Linda Henry, Mark Wymer. Hepatology 2016
15

MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study.
Philip D Ambery, Sebastian Klammt, Maximillian G Posch, Marcella Petrone, Wenji Pu, Cristina Rondinone, Lutz Jermutus, Boaz Hirshberg. Br J Clin Pharmacol 2018
41
24

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.
Mohammed Eslam, Arun J Sanyal, Jacob George. Gastroenterology 2020
990
15


GLP-1 Receptor Expression Within the Human Heart.
Laurie L Baggio, Bernardo Yusta, Erin E Mulvihill, Xiemin Cao, Catherine J Streutker, Jagdish Butany, Thomas P Cappola, Kenneth B Margulies, Daniel J Drucker. Endocrinology 2018
116
13

Mechanisms of NAFLD development and therapeutic strategies.
Scott L Friedman, Brent A Neuschwander-Tetri, Mary Rinella, Arun J Sanyal. Nat Med 2018
13

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
163
13

GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
Charles Pyke, R Scott Heller, Rikke K Kirk, Cathrine Ørskov, Steffen Reedtz-Runge, Peter Kaastrup, Anders Hvelplund, Linda Bardram, Dan Calatayud, Lotte Bjerre Knudsen. Endocrinology 2014
452
13

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
13

Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Keyur Patel, Stephen A Harrison, Magdy Elkhashab, James F Trotter, Robert Herring, Sergio E Rojter, Zeid Kayali, Vincent Wai-Sun Wong, Susan Greenbloom, Saumya Jayakumar,[...]. Hepatology 2020
124
13

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Eduardo Vilar-Gomez, Yadina Martinez-Perez, Luis Calzadilla-Bertot, Ana Torres-Gonzalez, Bienvenido Gra-Oramas, Licet Gonzalez-Fabian, Scott L Friedman, Moises Diago, Manuel Romero-Gomez. Gastroenterology 2015
13

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J Sanyal. Hepatology 2018
13


Once-Weekly Semaglutide in Adults with Overweight or Obesity.
John P H Wilding, Rachel L Batterham, Salvatore Calanna, Melanie Davies, Luc F Van Gaal, Ildiko Lingvay, Barbara M McGowan, Julio Rosenstock, Marie T D Tran, Thomas A Wadden,[...]. N Engl J Med 2021
437
13

NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Stephen A Harrison, Mary E Rinella, Manal F Abdelmalek, James F Trotter, Angelo H Paredes, Hays L Arnold, Marcelo Kugelmas, Mustafa R Bashir, Mark J Jaros, Lei Ling,[...]. Lancet 2018
263
12

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes.
Gregory Gaich, Jenny Y Chien, Haoda Fu, Leonard C Glass, Mark A Deeg, William L Holland, Alexei Kharitonenkov, Thomas Bumol, Holger K Schilske, David E Moller. Cell Metab 2013
597
12

Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
331
12

Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.
Alice E Adriaenssens, Emma K Biggs, Tamana Darwish, John Tadross, Tanmay Sukthankar, Milind Girish, Joseph Polex-Wolf, Brain Y Lam, Ilona Zvetkova, Warren Pan,[...]. Cell Metab 2019
93
12

Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis.
Chrysi Koliaki, Julia Szendroedi, Kirti Kaul, Tomas Jelenik, Peter Nowotny, Frank Jankowiak, Christian Herder, Maren Carstensen, Markus Krausch, Wolfram Trudo Knoefel,[...]. Cell Metab 2015
505
12

A role for glucagon-like peptide-1 in the central regulation of feeding.
M D Turton, D O'Shea, I Gunn, S A Beak, C M Edwards, K Meeran, S J Choi, G M Taylor, M M Heath, P D Lambert,[...]. Nature 1996
12

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Stephen A Harrison, Mustafa R Bashir, Cynthia D Guy, Rong Zhou, Cynthia A Moylan, Juan P Frias, Naim Alkhouri, Meena B Bansal, Seth Baum, Brent A Neuschwander-Tetri,[...]. Lancet 2019
224
12

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
12

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
Qian Zhang, Challa Tenagne Delessa, Robert Augustin, Mostafa Bakhti, Gustav Colldén, Daniel J Drucker, Annette Feuchtinger, Cristina Garcia Caceres, Gerald Grandl, Alexandra Harger,[...]. Cell Metab 2021
52
15

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Juan P Frías, Melanie J Davies, Julio Rosenstock, Federico C Pérez Manghi, Laura Fernández Landó, Brandon K Bergman, Bing Liu, Xuewei Cui, Katelyn Brown. N Engl J Med 2021
166
12

Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
Samer Gawrieh, Mazen Noureddin, Nicole Loo, Rizwana Mohseni, Vivek Awasty, Kenneth Cusi, Kris V Kowdley, Michelle Lai, Eugene Schiff, Deven Parmar,[...]. Hepatology 2021
58
13

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
Mohammad Shafi Kuchay, Sonal Krishan, Sunil Kumar Mishra, Khalid Jamal Farooqui, Manish Kumar Singh, Jasjeet Singh Wasir, Beena Bansal, Parjeet Kaur, Ganesh Jevalikar, Harmendeep Kaur Gill,[...]. Diabetes Care 2018
268
10


Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
Matthew J Armstrong, Diana Hull, Kathy Guo, Darren Barton, Jonathan M Hazlehurst, Laura L Gathercole, Maryam Nasiri, Jinglei Yu, Stephen C Gough, Philip N Newsome,[...]. J Hepatol 2016
212
10



Glucagon increases energy expenditure independently of brown adipose tissue activation in humans.
V Salem, C Izzi-Engbeaya, C Coello, D B Thomas, E S Chambers, A N Comninos, A Buckley, Z Win, A Al-Nahhas, E A Rabiner,[...]. Diabetes Obes Metab 2016
90
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.